Latest Ibritumomab tiuxetan Stories
THE TOBACCO plant - responsible for millions of cancer cases - may actually offer the means to treat one form of the disease, a study says. US scientists used the plant to "grow" key components of a cancer vaccine.
SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S.
Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets.
SEATTLE, July 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
By Wahl, Richard L Many of us remember the 1989 film Field of Dreams, starring Kevin Costner. In brief, the main character becomes convinced that a baseball field must be built on his failing farmland. Another character assures him that if he builds it, "they" will come.
SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle.
Cell Therapeutics has signed an agreement with Bayer Schering Pharma to gain access to Bayer's Phase III Zevalin first-line Indolent trial data.
SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today an agreement with Bayer Schering Pharma to gain access to Bayer's phase III Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent Trial, FIT data.
COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced results of a three-arm phase 3 clinical trial that show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated with the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy...
ROCHESTER, N.Y., March 5 /PRNewswire/ -- Vaccinex, Inc. announced today that Dr. John E. Leonard has joined its Scientific Advisory Board, and will be actively involved in the strategic planning and execution of the company's therapeutic antibody development programs. Dr.
- To give a box on the ear to.